GSK Awarded Three-Year Contract To Supply British Government With HPV Vaccine Cervarix
GlaxoSmithKline announced on Wednesday that it has received a three-year contract from the United Kingdom’s Department of Health to supply the country’s immunization program with its human papillomavirus vaccine Cervarix, the Wall Street Journal reports. The health department’s goal is to vaccinate all girls ages 12 to 13 with Cervarix to protect against cervical cancer. GSK will sell Cervarix, administered in a three-shot series, to the state health system.
